Pharmacy
Pharmacy Formulary and Prior Authorization Changes For July 2025
May 7, 2025
Beginning July 2025, some drugs will experience a formulary drug list change. Visit premera.com to learn more about these changes.
Also, beginning July 2025, the following drugs will require a new prior authorization:
Condition
Drugs requiring new prior authorization
Preferred alternative
Cancer support
- Nyvepria (pegfilgrastim-apgf)
- Fulphila (pegfilgrastim-jmdb)
- Udenyca (pegfilgrastim-cbqv)
- Udenyca On-body (pegfilgrastim-cbqv)
Inflammatory disease
- Humira (adalimumab)
- Adalimumab-adaz
- Adalimumab-adbm
- Adalimumab-ryvk
- Cyltezo (adalimumab-adbm)
- Simlandi (adalimumab-ryvk)
How we’re notifying members: Impacted members received a letter in the mail in May 2025 notifying them of the change or the members’ provider was notified of the change in our February 2025 Provider News.
If you have any questions about these formulary and prior authorization changes, please contact your Premera representative.